iBio Inc
IBIO1.980USD
+0.100+5.32%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
40.10MMarket Cap
LossP/E TTM
More Details of iBio Inc Company
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
iBio Inc Info
Ticker SymbolIBIO
Company nameiBio Inc
IPO dateAug 18, 2008
CEOBrenner (Martin B)
Number of employees20
Security typeOrdinary Share
Fiscal year-endAug 18
Address11750 Sorrento Valley Road
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone19794460027
Websitehttps://ibioinc.com/
Ticker SymbolIBIO
IPO dateAug 18, 2008
CEOBrenner (Martin B)
Company Executives of iBio Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Felipe Duran
Mr. Felipe Duran
Chief Financial Officer
Chief Financial Officer
11.14K
--
Mr. Marc Banjak
Mr. Marc Banjak
Chief Legal Counsel
Chief Legal Counsel
11.07K
--
Mr. William D. (Chip) Clark
Mr. William D. (Chip) Clark
Independent Chairman of the Board
Independent Chairman of the Board
1.84K
--
Mr. Antonio Parada
Mr. Antonio Parada
Independent Director
Independent Director
--
--
Mr. David A. Arkowitz
Mr. David A. Arkowitz
Independent Director
Independent Director
--
--
Dr. Alexandra Kropotova, M.D.
Dr. Alexandra Kropotova, M.D.
Independent Director
Independent Director
--
-100.00%
Mr. Evert B. (Eef) Schimmelpennink
Mr. Evert B. (Eef) Schimmelpennink
Independent Director
Independent Director
--
--
Dr. Martin B. Brenner, Ph.D.
Dr. Martin B. Brenner, Ph.D.
Chief Executive Officer, Chief Scientific Officer, Director
Chief Executive Officer, Chief Scientific Officer, Director
--
--
Mr. Gary L. Sender
Mr. Gary L. Sender
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Felipe Duran
Mr. Felipe Duran
Chief Financial Officer
Chief Financial Officer
11.14K
--
Mr. Marc Banjak
Mr. Marc Banjak
Chief Legal Counsel
Chief Legal Counsel
11.07K
--
Mr. William D. (Chip) Clark
Mr. William D. (Chip) Clark
Independent Chairman of the Board
Independent Chairman of the Board
1.84K
--
Mr. Antonio Parada
Mr. Antonio Parada
Independent Director
Independent Director
--
--
Mr. David A. Arkowitz
Mr. David A. Arkowitz
Independent Director
Independent Director
--
--
Dr. Alexandra Kropotova, M.D.
Dr. Alexandra Kropotova, M.D.
Independent Director
Independent Director
--
-100.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Dec 20
Updated: Sat, Dec 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
EcoR1 Capital, LLC
9.91%
SilverArc Capital Management, LLC
9.70%
Frazier Life Sciences Management, L.P.
8.69%
Lynx1 Capital Advisors LLC
7.36%
Ikarian Capital LLC
2.67%
Other
61.67%
Shareholders
Shareholders
Proportion
EcoR1 Capital, LLC
9.91%
SilverArc Capital Management, LLC
9.70%
Frazier Life Sciences Management, L.P.
8.69%
Lynx1 Capital Advisors LLC
7.36%
Ikarian Capital LLC
2.67%
Other
61.67%
Shareholder Types
Shareholders
Proportion
Hedge Fund
15.04%
Investment Advisor/Hedge Fund
13.85%
Investment Advisor
9.13%
Private Equity
8.69%
Individual Investor
3.56%
Research Firm
0.19%
Other
49.55%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
59
3.36M
17.09%
+398.32K
2025Q2
72
3.23M
19.57%
-548.11K
2025Q1
74
3.37M
20.42%
+306.89K
2024Q4
74
2.64M
26.79%
-702.17K
2024Q3
90
2.62M
31.20%
-328.88K
2024Q2
97
2.46M
29.41%
-677.88K
2024Q1
135
2.90M
34.96%
+2.56M
2023Q4
142
266.76K
13.65%
+141.65K
2023Q3
152
62.31K
5.75%
-87.82K
2023Q2
164
77.61K
9.94%
-78.78K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lynx1 Capital Advisors LLC
1.54M
7.95%
+676.29K
+78.43%
Jun 30, 2025
Ikarian Capital LLC
599.91K
3.1%
--
--
Jun 30, 2025
Crutcher (Patrick J)
546.61K
2.7%
-150.11K
-21.55%
Jun 30, 2025
Opaleye Management Inc.
375.00K
1.85%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
143.86K
0.71%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 26, 2023
Merger
20→1
Oct 26, 2023
Merger
20→1
Oct 26, 2023
Merger
20→1
Oct 26, 2023
Merger
20→1
Sep 27, 2022
Merger
25→1
Sep 27, 2022
Merger
25→1
Date
Type
Ratio
Oct 26, 2023
Merger
20→1
Oct 26, 2023
Merger
20→1
Oct 26, 2023
Merger
20→1
Oct 26, 2023
Merger
20→1
Sep 27, 2022
Merger
25→1
Sep 27, 2022
Merger
25→1
Sep 27, 2022
Merger
25→1
Sep 27, 2022
Merger
25→1
FAQs
Who are the top five shareholders of iBio Inc?
The top five shareholders of iBio Inc are:
Lynx1 Capital Advisors LLC holds 1.54M shares, accounting for 7.95% of the total shares.
Ikarian Capital LLC holds 599.91K shares, accounting for 3.10% of the total shares.
Crutcher (Patrick J) holds 546.61K shares, accounting for 2.70% of the total shares.
Opaleye Management Inc. holds 375.00K shares, accounting for 1.85% of the total shares.
The Vanguard Group, Inc. holds 143.86K shares, accounting for 0.71% of the total shares.
Lynx1 Capital Advisors LLC holds 1.54M shares, accounting for 7.95% of the total shares.
Ikarian Capital LLC holds 599.91K shares, accounting for 3.10% of the total shares.
Crutcher (Patrick J) holds 546.61K shares, accounting for 2.70% of the total shares.
Opaleye Management Inc. holds 375.00K shares, accounting for 1.85% of the total shares.
The Vanguard Group, Inc. holds 143.86K shares, accounting for 0.71% of the total shares.
What are the top three shareholder types of iBio Inc?
The top three shareholder types of iBio Inc are:
EcoR1 Capital, LLC
SilverArc Capital Management, LLC
Frazier Life Sciences Management, L.P.
EcoR1 Capital, LLC
SilverArc Capital Management, LLC
Frazier Life Sciences Management, L.P.
How many institutions hold shares of iBio Inc (IBIO)?
As of 2025Q3, 59 institutions hold shares of iBio Inc, with a combined market value of approximately 3.36M, accounting for 17.09% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -2.47%.
What is the biggest source of revenue for iBio Inc?
In --, the -- business generated the highest revenue for iBio Inc, amounting to -- and accounting for --% of total revenue.
